| __timestamp | Arrowhead Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 2983000000 |
| Thursday, January 1, 2015 | 34718089 | 3426000000 |
| Friday, January 1, 2016 | 40998209 | 3398000000 |
| Sunday, January 1, 2017 | 32022880 | 3878000000 |
| Monday, January 1, 2018 | 19110051 | 4056000000 |
| Tuesday, January 1, 2019 | 26556257 | 4381000000 |
| Wednesday, January 1, 2020 | 52275890 | 5151000000 |
| Friday, January 1, 2021 | 80981000 | 5246000000 |
| Saturday, January 1, 2022 | 124431000 | 5673000000 |
| Sunday, January 1, 2023 | 90932000 | 6090000000 |
| Monday, January 1, 2024 | 98761000 | 6091000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. Gilead Sciences, a giant in the biotech sector, consistently outspent Arrowhead Pharmaceuticals, with its SG&A expenses peaking at approximately $6 billion in 2023. In contrast, Arrowhead's expenses showed a steady increase, reaching around $124 million in 2022, marking a fivefold rise since 2014. This trend highlights Gilead's expansive operational scale compared to Arrowhead's more modest growth trajectory. Notably, data for Gilead in 2024 is missing, indicating potential shifts or reporting delays. As the industry faces new challenges and opportunities, these financial insights offer a glimpse into the strategic priorities of these pharmaceutical leaders.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and BeiGene, Ltd.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Incyte Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Pharming Group N.V.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Ionis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Alkermes plc
Gilead Sciences, Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Gilead Sciences, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Zoetis Inc. or Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: SG&A Expense Trends
Comparing SG&A Expenses: Arrowhead Pharmaceuticals, Inc. vs Travere Therapeutics, Inc. Trends and Insights